External validity of the ARISTOTLE trial in real-life atrial fibrillation patients

Cardiovascular Therapeutics

Volumn 32, Issue 5, 2014, Pages 214-218

  Hägg, Lovisa ^a   Johansson, Cecilia ^a   Jansson, Jan Håkan ^a   Johansson, Lars ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Apixaban; ARISTOTLE; Arrhythmias; Atrial fibrillation; Coagulation Thrombosis; External validity

Indexed keywords

ANTICOAGULANT AGENT;

AGED; ATRIAL FIBRILLATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; INFANT; MALE; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CROSS-SECTIONAL STUDIES; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INFANT; MALE;

EID: 84908403356     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12087     Document Type: Article

References (22)

1. Furberg CD, Soliman EZ. Double-blindness protects scientific validity. J Thromb Haemost 2008;6:230-231.
2. Parker RA. Studies should be controlled, randomized, and blinded. Clin Pharmacol Ther 2009;85:461-463.
3. Mortensen J, Thygesen SS, Johnsen SP, Vinther PM, Kristensen SD, Refsgaard J. Incidence of bleeding in 'real-life' acute coronary syndrome patients treated with antithrombotic therapy. Cardiology 2008;111:41-46.
4. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003;48:313-318.
5. Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol 2012;10:1002-1007; quiz e78.
6. Chiò A, Canosa A, Gallo S, et al. ALS clinical trials: do enrolled patients accurately represent the ALS population? Neurology 2011;77:1432-1437.
7. Saunders C, Byrne CD, Guthrie B, et al. External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? Diabet Med 2013;30:300-308.
8. Apisarnthanarax S, Swisher-McClure S, Chiu WK, Kimple RJ, Harris SL, Morris DE, Tepper JE. Applicability of randomized trials in radiation oncology to standard clinical practice. Cancer 2013;119:3092-3099.
9. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
10. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
11. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.
12. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-2104.
13. Norberg J, Bäckström S, Jansson JH, Johansson L. Estimating the prevalence of atrial fibrillation in a general population using validated electronic health data. Clin Epidemiol 2013;5:475-481.
14. Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010;159:331-339.
15. Lee S, Monz BU, Clemens A, Brueckmann M, Lip GY. Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database. BMJ Open 2012;2:e001768.
16. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-1420.
17. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-1413.
18. Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013;34:2094-2106.
19. Beyer-Westendorf J, Büller H. External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different? J Thromb Haemost 2011;9:2153-2158.
20. Büller HR, Halperin JL, Bounameaux H, Prins M. Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants. J Thromb Haemost 2008;6:227-229.
21. Mant D. Can randomised trials inform clinical decisions about individual patients? Lancet 1999;353:743-746.
22. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet 2005;365:82-93.